|
-- back to lectures --
|
| |
| Course Title: |
|
“The Burden of IBD” from the 2009 GI Forum, “Inflammatory Bowel Disease” |
|
|
|
| |
| |
Credit Hours: |
0.5 |
| Valid Until: |
02/31/2011 |
|
| |
Lecturer: |
Dr. Charles N. Bernstein |
|
Date Released: |
2/5/2010 |
|
| |
Affiliation: |
Professor of Medicine
Head, Section of Gastroenterology
Director, University of Manitoba
IBD Clinical & Research Centre
Winnipeg, Manitoba, Canada |
| |
|
| |
View the Post-Test
|
| |
|
| |
| |
Lecture Overview: |
| |
| |
Dr. Bernstein discusses the burden of IBD from a Canadian context. The doctor presents population based epidemiological data of IBD in Canada and that approximately 200,000 Canadians have IBD which is comparable to the number of Canadians with Type I diabetes or epilepsy and nearly 4 times as great as the number with HIV or multiple sclerosis. The peak age of onset is in the second decade and there is an equal; sex ratio in ulcerative colitis with more females than males with Crohn's disease. Manitoba data show that Native or Aboriginal Canadians are significantly less likely to have IBD than white Canadians. Furthermore, IBD is more common among persons in the upper one third of socioeconomic status and is also more common persons with a low rate of reportable enteric infections. The burden of IBD to the patient encompasses a wide range of non-gastrointestinal complications ranging from other chronic immune diseases of the skin, hepatobiliary tract, joints and eyes to osteoporosis and fractures and to thromboembolic disease. The burden to society includes the high rate of health care utilization by patients with IBD including, significantly more outpatient visits, surgeries and hospitalizations than non IBD controls. Among newly diagnosed patients with IBD when followed over 15 years, 47% of Crohn's disease patients and 21% of ulcerative colitis patients will get admitted to hospital and of those admitted 35% will be readmitted within 7 years. |
| |
|
| |
| |
Target Audience: |
| |
| |
This activity is intended for Gastroenterology and select Internal Medicine healthcare professionals. |
| |
|
| |
| |
Objectives: |
| |
| |
Following this program, participants will be able to demonstrate the following improvements:- Know the incidence rate of Crohn's disease and ulcerative colitis in Canada and how that compares to recent data from around the world
- Be familiar with several of the non gastrointestinal complications of IBD
- Be familiar with likelihood patients with IBD will get admitted to hospital.
|
| |
|
| |
| |
Lecturer Disclosure Statement: |
| |
| |
Dr. Bernstein has received honoraria from Abbott Labs Canada and Shire Pharmaceuticals Canada for serving on advisory boards. |
| |
|
| |
| |
Accreditation Statement: |
| |
| |
Medical Education Conferences, Inc. designates this educational activity for a maximum of 0.5 AMA PRA Category 1 credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. |
| |
|
|
|
